Assertio revenues

As part of its pivot away from pain drugs, Assertio Therapeutics sold the rights of its bestselling painkiller, Nucynta, to Collegium Pharmaceutical in 2017. But the Lake Forest drugmaker still gets more than half its revenue from payments related to the opioid.

Note: Data for Q2 for both years. Chart excludes sales reserve estimate adjustments for Nucynta products (licensed to Collegium in 2017) and Lazanda (divested in November 2017), which account for less than 1 percent of total revenue.